The US Food and Drug Administration (FDA) is set to convene a significant public hearing on June 12, 2026, a…
Read More
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
On May 12, 2025, a significant executive order signed by then-US President Donald Trump mandated the US Department of Health…
Read More
Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025
Eli Lilly and Company has officially ascended to the pinnacle of the global pharmaceutical industry, achieving the coveted position of…
Read More
Viz.ai and Alnylam Forge Strategic Alliance to Revolutionize Cardiac Amyloidosis Diagnosis and Care
In a significant development poised to reshape the landscape of cardiovascular medicine, Viz.ai has announced a groundbreaking collaboration with Alnylam…
Read More
MSD Acquires Terns Pharmaceuticals for $6.7 Billion in Strategic Move to Bolster Oncology Pipeline Ahead of Keytruda Patent Expiry
In a significant development poised to reshape the competitive landscape of cancer therapeutics, global pharmaceutical giant MSD (known as Merck…
Read More
The Rise of AI-Driven Autonomous Laboratories: Reshaping Pharmaceutical R&D
The landscape of pharmaceutical research and development (R&D) is undergoing a profound transformation, driven by the increasing integration of artificial…
Read More
Sanofi Secures Global Rights to Kali Therapeutics’ Promising Tri-Specific Antibody KT501 for Autoimmune Diseases in a Landmark $1.23 Billion Deal
Sanofi has entered into an exclusive global license agreement with Kali Therapeutics, a significant move that grants the pharmaceutical giant…
Read More
Monash University and ClinChoice Forge Strategic Alliance to Accelerate Therapeutic Development and Enhance Patient Access to Novel Treatments
Australia’s Monash University, a leading research institution, and ClinChoice, a global contract research organization (CRO), have formally announced a significant…
Read More
Gilead Sciences to Acquire Ouro Medicines for $2.2 Billion, Ushering in New Era of T-Cell Engagers in Autoimmune Diseases
Gilead Sciences is poised to make a significant entry into the burgeoning field of T-cell engagers (TCEs) with its $2.2…
Read More
Pharma 2035 Playbook: Speed, focus and conviction in an uncertain world
The pharmaceutical industry, perpetually at the vanguard of scientific innovation, finds itself navigating an increasingly turbulent global landscape. Characterized by…
Read More
